# Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy.

> PubMed lists PMID 19219409 in Advances in therapy as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2009-02-14 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-19219409-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-19219409-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-19219409-exenatide-v1.json
- Content SHA-256: `623902d569767b42ae1754bb4ea663abf7d1404b796e8dd5223470964793b6c2`

## Claims and source pins

### Headline

Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy. ([`pubmed-observation-pmid-19219409-2026-01-28-629863bb85d8`](#source-pubmed-observation-pmid-19219409-2026-01-28-629863bb85d8))

### Summary

PubMed lists PMID 19219409 in Advances in therapy as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2009-02-14 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-19219409-2026-01-28-629863bb85d8`](#source-pubmed-observation-pmid-19219409-2026-01-28-629863bb85d8))

### Paragraph 1

PubMed lists PMID 19219409 in Advances in therapy as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2009-02-14 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-19219409-2026-01-28-629863bb85d8`](#source-pubmed-observation-pmid-19219409-2026-01-28-629863bb85d8))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-19219409-2026-01-28-629863bb85d8`](#source-pubmed-observation-pmid-19219409-2026-01-28-629863bb85d8))

## Sources

<a id="source-pubmed-observation-pmid-19219409-2026-01-28-629863bb85d8"></a>
- **Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy. · retained source version 1:2026-01-28:current:629863bb85d8032a9c1436928a15ec9f6730c0928d8fc669a8525b2be0a76df2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/19219409/) (`pubmed-observation-pmid-19219409-2026-01-28-629863bb85d8`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-19219409-exenatide-v1.json SHA-256: 623902d569767b42ae1754bb4ea663abf7d1404b796e8dd5223470964793b6c2.